

Type II DNA topoisomerase inhibitors - Pipeline Insight, 2022

<https://marketpublishers.com/r/T62097F4CD1CEN.html>

Date: January 2022

Pages: 85

Price: US\$ 2,000.00 (Single User License)

ID: T62097F4CD1CEN

Abstracts

This report can be delivered to the clients within 3-4 Business Days

DelveInsight's, "Type II DNA topoisomerase inhibitors - Pipeline Insight, 2022" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Type II DNA topoisomerase inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Type II DNA topoisomerase inhibitors Understanding

Type II DNA topoisomerase inhibitors: Overview

Type II topoisomerases are ubiquitous enzymes that play an essential role in the control of replicative DNA synthesis and share structural and functional homology among different prokaryotic and eukaryotic organisms. Small molecules that target type II topoisomerase are divided into two classes: inhibitors and poisons. Due to their frequent presence in proliferating eukaryotic cells, inhibitors of type II topoisomerases have been extensively studied and used as anti-cancer medications.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Type II DNA topoisomerase inhibitors R&D. The therapies under development are focused on novel approaches for Type II DNA topoisomerase inhibitors.

Type II DNA topoisomerase inhibitors Emerging Drugs Chapters

This segment of the Type II DNA topoisomerase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Type II DNA topoisomerase inhibitors Emerging Drugs

TRP-1001: Tryp Therapeutics

Tryp is developing TRP-1001, an oral formulation of razoxane for the treatment of soft tissue sarcoma. Currently, it is in Phase II stage of development to treat soft tissue sarcoma.

Mitoxantrone liposomal: CSPC ZhongQi Pharmaceutical Technology

A liposomal formulation of mitoxantrone is being developed by CSPC ZhongQi Pharmaceutical Technology, for the treatment of solid tumours and lymphoma. Currently, it is in preregistration stage of development to treat Peripheral T-cell lymphoma.

Further product details are provided in the report.....

Type II DNA topoisomerase inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Type II DNA topoisomerase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Type II DNA topoisomerase inhibitors

There are approx. 30+ key companies which are developing the Type II DNA topoisomerase inhibitors. The companies which have their Type II DNA topoisomerase inhibitors drug candidates in the most advanced stage, i.e. Preregistration include, CSPC ZhongQi Pharmaceutical Technology.

Phases

DelveInsight's report covers around 30+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Type II DNA topoisomerase inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Type II DNA topoisomerase inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Type II DNA topoisomerase inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Type II DNA topoisomerase inhibitors drugs.

Type II DNA topoisomerase inhibitors Report Insights

Type II DNA topoisomerase inhibitors Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Type II DNA topoisomerase inhibitors Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

How many companies are developing Type II DNA topoisomerase inhibitors drugs?

How many Type II DNA topoisomerase inhibitors drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for

the treatment of Type II DNA topoisomerase inhibitors?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Type II DNA topoisomerase inhibitors therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Type II DNA topoisomerase inhibitors and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Tryp Therapeutics

CSPC ZhongQi Pharmaceutical Technology

Oasmia Pharmaceutical

Aradigm

Teclison

Denovo Biopharma

NanoCarrier

EnGeneIC

Avacta

Shasqi

SkinJect

Lantern Pharma

Double Bond Pharmaceutical

POP Biotechnologies

LIDDS

TenNor Therapeutics

Exelixis

EnGeneIC

Key Products

TRP-1001

Mitoxantrone liposomal

Doxophos

Apulmiq

Tirazone

DB 106

NC 6003

VEDVDox

AVA 6000

SQ 3370

Doxorubicin-containing MNA

LP 184

SA 033

Doxorubicin/Porphyrin phospholipid nanoparticles

NZ DOX

PNU-159682 based antibody drug conjugate

E-EDV-D682

Contents

Introduction

Executive Summary

Type II DNA topoisomerase inhibitors: Overview

Structure

Mechanism of Action

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Type II DNA topoisomerase inhibitors – DelveInsight's Analytical Perspective

Late Stage Products (Preregistration)

Comparative Analysis

Mitoxantrone liposomal: CSPC ZhongQi Pharmaceutical Technology

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

TRP-1001: Tryp Therapeutics

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I and I/II)

Comparative Analysis

NC 6003: NanoCarrier

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Pre-clinical and Discovery Stage Products

Comparative Analysis
NZ DOX: LIDDS
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.....
Inactive Products
Comparative Analysis
Type II DNA topoisomerase inhibitors Key Companies
Type II DNA topoisomerase inhibitors Key Products
Type II DNA topoisomerase inhibitors- Unmet Needs
Type II DNA topoisomerase inhibitors- Market Drivers and Barriers
Type II DNA topoisomerase inhibitors- Future Perspectives and Conclusion
Type II DNA topoisomerase inhibitors Analyst Views
Type II DNA topoisomerase inhibitors Key Companies
Appendix

I would like to order

Product name: Type II DNA topoisomerase inhibitors - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/T62097F4CD1CEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T62097F4CD1CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970